Immunic receives notice of allowance for united states patent protecting the treatment of relapsing multiple sclerosis with vidofludimus and its salts

New york , nov. 2, 2023 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a notice of allowance from the united states patent and trademark office (uspto) for patent application 17/391,442, entitled, "treatment of multiple sclerosis comprising dhodh inhibitors," covering a daily dose of about 10 mg to 45 mg of vidofludimus calcium (imu-838) and other salt as well as free acid forms for the treatment of relapsing multiple sclerosis (rms). the claims are expected to provide protection into 2041, unless extended further.
IMUX Ratings Summary
IMUX Quant Ranking